Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
about
Update in Cystic Fibrosis 2014Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implicationsNew and emerging targeted therapies for cystic fibrosisTargeted therapies to improve CFTR function in cystic fibrosisCystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsPaediatrics: messages from MunichIn vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Cystic Fibrosis Gene Therapy in the UK and Elsewhere.Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Cystic fibrosis: a model system for precision medicine.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic FibrosisCFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis.Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.A new era of personalized medicine for cystic fibrosis - at last!New and Emerging Treatments for Cystic Fibrosis.Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.2014 year in review: Cystic fibrosis.Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell.Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.Biomarkers for cystic fibrosis drug development.A safety evaluation of ivacaftor for the treatment of cystic fibrosis.New drug developments in the management of cystic fibrosis lung disease.New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Pharmacogenetics of cystic fibrosis treatment.Individualized medicine using intestinal responses to CFTR potentiators and correctors.Cystic fibrosis: a clinical view.The use of ivacaftor in CFTR mutations resulting in residual functioning protein.Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.Strategies for the etiological therapy of cystic fibrosis.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice.Breathing Easier: A Well-tolerated Corrector for F508del.
P2860
Q22306307-FBBC81B3-0917-4895-B219-C136C5450ED3Q26747065-BF77675E-D7EC-4DF7-A8AA-953FB7AD07F5Q26749278-97E503D6-85F1-4020-946F-6C3A828B1663Q26781441-472FFEE6-5DE9-4E5F-80C8-C611CA246C8DQ28073063-527FCC02-CD03-46C9-8331-5EEB2FC6D3A4Q28073996-FDD96E6E-5099-43E7-884D-98DC967E87D0Q28077411-D6671C74-197A-42DA-BE18-E0B1AF65CC77Q28596759-62854D3F-6A0C-4B9D-951A-57CE874E7121Q33769791-FC52E018-2B15-498D-86EA-3389344E55D5Q34496122-B4F3B439-C7DD-41B5-9004-92529F27C27DQ35641704-35BD3724-1DFA-4730-91C4-4081AB61C7BFQ35659323-A378FB1B-EB16-4017-8708-2318E8D6B070Q35810699-DD63EBE3-26FA-4CA0-AA81-6D6BA0AAEC94Q36213685-6D7B7971-3E0B-4DCD-9A59-C61920785505Q36269320-D7CFF5EA-EB1F-46CE-A8E4-7FBA1D3FCE64Q36609344-BC1F7033-8F0A-4024-857C-58CB6A716B58Q37097931-C5B27DAE-F7EB-4B2D-8452-5AD5656B55E1Q37241563-233AB5B1-FFDF-4675-A7EE-A191ADEBA802Q37583400-32ECB1F6-E3D7-4332-9375-5D6F5A72F707Q38528320-AC3E9D1B-4BF9-4C6F-B478-50BE72B791FFQ38530276-C5E38206-BBFE-4E82-A2A2-B3EA06A10794Q38532426-2CF05489-C530-4F84-9410-65F28A4A40DAQ38533943-45B1A492-A7F7-42B9-82EB-BDE68B15A957Q38582563-A97110F7-CA97-4E41-A8C1-93F61ABBAE25Q38633196-A9CEAF4E-E89D-48EB-A944-4F46635B1B03Q38746661-5E12FB7C-1594-4CC9-A371-CA5C36AE97E5Q38755600-856019D0-039B-4411-BD7C-4100BE64FD22Q38770171-BE9D8DB8-54EF-49A4-B790-D21A214B0519Q38790382-158333A4-D110-450C-B878-72876E4D0288Q38836754-73EA0B6F-C115-4E73-B04E-01B9A7612F03Q38918082-BD7C03D4-0596-4F31-B215-0C8338884920Q38962735-B2D35B05-3718-49C8-93AC-B6C57033B281Q38973292-5B3FE0CB-A17C-4789-AD33-E4BF52E8A141Q39216570-D32A8FE5-DAC0-4325-8226-3911A5960040Q41287880-48735154-A3F1-4187-969F-0771CFEEF196Q41641680-6B718ABC-136D-43DF-A8C3-04E55BE09A23Q42650380-96B5F052-509D-473B-B4C3-97B554B13861Q43538692-55A050C3-6470-465B-A0A2-60E6760EE379Q47729413-5033CED8-9FDC-408F-9E45-6EA3BBB81F2EQ47739415-38698F3C-DC45-4913-8FA5-BFE83988C5B5
P2860
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@ast
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@en
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@nl
type
label
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@ast
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@en
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@nl
prefLabel
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@ast
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@en
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@nl
P2093
P1476
Efficacy and safety of ivacaft ...... d a non-G551D gating mutation.
@en
P2093
Albert Faro
Anne Munck
Geoffrey Gilmartin
Kris De Boeck
Mark Higgins
Peter Hiatt
Seth Walker
P304
P356
10.1016/J.JCF.2014.09.005
P577
2014-09-26T00:00:00Z